2-hydrazineyl-5-methylpyridine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-hydrazineyl-5-methylpyridine hydrochloride
• 英文别名: 2-hydrazino-5-methylpyridine hydrochloride；2-Hydrazinyl-5-methylpyridine hydrochloride；(5-methylpyridin-2-yl)hydrazine;hydrochloride
• 化学式: C₆H₉N₃*ClH
• 分子量: 159.618
• InChiKey: AUKAAEWWXWCHBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.9
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-甲基喹啉 、 2-hydrazineyl-5-methylpyridine hydrochloride 在 碘 、 potassium carbonate 、 二甲基亚砜 作用下， 以46%的产率得到4-(6-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-yl)quinoline
  参考文献：
  名称：

  甲基氮杂杂环芳烃的氧化性C（sp 3）–H功能化：1,2,4-三唑并[4,3- a ]吡啶的简便途径

  摘要：

  我们在本文中描述了在I 2 -DMSO存在下用于制备1,2,4-三唑并[4,3- a ]吡啶的氧化[4 +1]环。该协议能够通过2-甲基-氮杂杂环芳烃的sp 3 C–H键的直接氧化功能合成三唑并[4，3 - a ]吡啶-喹啉连接的二杂环。该反应显示出较宽的底物范围和良好的官能团耐受性。

  DOI：

  10.1039/c9ob00033j

文献信息

• FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd

  公开号：EP3653625A1

  公开（公告）日：2020-05-20

  The present inventon provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is -C(=O)- or the like; L3 is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.

  本发明提供下式 (I) 所代表的化合物： 其中一个分子由式： 或类似物； y 是 0 或 1； R1 是氢或类似物； R2a 和 R2b 与相邻碳原子结合形成环 B； 环 B 是取代或未取代的非芳香族碳环或类似物； R3a 是氢或类似物； R3b 是氢或类似物； R4a 由式表示： L1 是单键或类似物；L2 是 -C(=O)- 或类似物；L3 是单键或类似物；R7 是取代或未取代的烷基或类似物；R4b 是取代或未取代的烷基或类似物；R4c 各自独立地是卤素或类似物。
• Fused ring derivative having MGAT-2 inhibitory activity
  申请人：Shionogi & Co., Ltd.

  公开号：US11198695B2

  公开（公告）日：2021-12-14

  The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

  本发明提供了下式 (I) 所代表的化合物： 其中由式 或类似符号。符号在说明书中定义。本发明的化合物具有 MGAT2 抑制活性，可作为治疗肥胖、代谢综合征、高脂血症、高甘油三酯血症、高 VLDL-三甘油三酯血症、高脂肪血症、糖尿病和动脉硬化等 MGAT2 相关疾病的药物。
• WO2019241796A5
  申请人：——

  公开号：WO2019241796A5

  公开（公告）日：2022-06-22
• EP3653625
  申请人：——

  公开号：——

  公开（公告）日：——
• PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA
  申请人：REATA PHARMACEUTICALS, INC.

  公开号：US20210292281A1

  公开（公告）日：2021-09-23

  Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and RORγ. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.